INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow Shareholders, As we reflect on 2025, ...

DENVER (AP) — Benita Fitzgerald Mosley has stood at the top of the podium at the Olympics. She's been part of fix-it projects and start-ups in that world, as well. None of those roles have presented ...

) has been revised to $5.36 / share. This is a decrease of 37.50% from the prior estimate of $8.57 dated December 3, 2025. The price target is an average of many targets provided by analysts. The ...

Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categoriesReader ...

Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market Company ...

Shiong, ImmunityBio Inc., and its leaders have defeated a shareholder challenge to a financing arrangement amid pending ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the Stocks to Buy Under $10 with High Potential. On January 15, Soumit Roy from JonesTrading reiterated a Buy rating on the stock and raised the price target ...

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial ...

To learn more about Imbed Biosciences and its innovative wound care technologies, please visit "The strategic investment from BioLab Holdings marks a pivotal moment for Imbed Biosciences," said Terry ...

A financing arrangement between biotech billionaire Dr. Patrick Soon-Shiong and ImmunityBio Inc. helped “bridge the gap” to ...

All right. Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Priyanka ...